06.19.26 -- Cut Development Timelines With Smarter Small Molecule Strategies

Get an overview of our AI-assisted early phase toolkit, which combines predictive modeling, formulation screening, and data-driven insights to accelerate molecule progression.

Gain insight into our approach designed to accelerate early-phase development through first-human-dose readiness, as well as its integrated partner network for targeted protein degraders.

We are a CDMO specializing in oral solid and non-sterile liquid dosage—from early formulation and clinical supplies to commercial manufacturing, packaging, analytics, and regulatory support.

Advanced particle engineering enhances the performance and life-cycle of therapeutics. Superior bioavailability, higher drug load, and improved stability are enabled for small and large molecules.

We support small molecule API synthesis projects from milligram to commercial quantities. We are the partner to address the most difficult challenges, whether the target is difficult to handle, synthesize, or source.

Integrated development and manufacturing approach combines formulation, clinical testing, and adaptive GMP production to accelerate decision‑making, reduce timelines, minimize API use, and improve small molecule outcomes.

Our network currently spans 9 manufacturing sites in 5 countries and can support discovery, preclinical, clinical, and commercial programs for New Chemical Entities. We have an innovative business model that does not add additional costs to your project.

Watch to discover the key benefits of outsourcing your OSD production and explore real-world examples and best practices to help you streamline your processes and enhance agility.

Align formulation, process, and scale strategy early to support larger batches, new equipment, and commercial manufacturing — cutting rework and speeding Phase I to launch.

An integrated path from formulation to commercial supply reduces risk, preserves product knowledge, and accelerates timelines — supported by sterile injectables expertise and reliable capacity.

Spray drying turns liquids into uniform powders, improving stability, solubility, flowability, and bioavailability while allowing precise control of particle traits.

Explore how a data‑driven discovery model combines DEL screening, computational insights, and medicinal chemistry to accelerate decisions, reduce risk, and enable efficient progression.

Critical formulation deficiencies were solved through rapid batch manufacturing and process adjustments. This enabled a 30% reduction in time-to-manufacture and prevented delays.